Many targets and drugs are being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease (NAFLD), but no one really knows which will turn out best for patients.
There is even a possibility researchers could turn to combinations of drugs with different mechanisms of action in order to...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
